Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of L04TD1 and L04RD1 in Healthy Volunteers
NCT05568121Phase 1Completed
- Sponsor
- Celltrion
- Start
- Sep 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of azilsartan medoxomil and amlodipine in essential hypertension (2 arms), sponsored by Celltrion. Primary endpoints: Area under the plasma concentration-time curve from time 0 to the last measurable concentration at 48 hours and Maximum Plasma Concentration at 48 hours. Started Sep 2022; status: completed.
02
Drugs
azilsartan medoxomilamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT05568121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05568121.